SYSTOLIC ARTERIAL HYPERTENSION: THE PLACE OF ANGIOTENSIN II RECEPTOR BLOCKERS

SYSTOLIC ARTERIAL HYPERTENSION: THE PLACE OF ANGIOTENSIN II RECEPTOR BLOCKERS

Systolic arterial hypertension: the place of angiotensin II receptor blockers.

Saved in:

Bibliographic Details
Main Author:	D. V. Nebieridze
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2002-02-01
Series:	Российский кардиологический журнал
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/1899
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
by: S. A. Boytsov, et al.
Published: (2016-01-01)

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?
by: V. V. Fomin, et al.
Published: (2007-06-01)

Arterial hypertension and coronary heart disease: the place of angiotensin II receptor antagonists
by: E. O. Taratukhin
Published: (2012-12-01)

Angiotensin II receptor inhibitors: role and place in arterial hypertension and metabolic syndrome treatment
by: I. N. Medvedev, et al.
Published: (2007-10-01)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
by: Myla E. Moretti, et al.
Published: (2012-01-01)

The impact of different angiotensin II receptor blockers on the stiffness of the large arteries and effectiveness of therapy
by: O. L. Rekovets, et al.
Published: (2022-12-01)

COMBINATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN HYPERTENSIVE PATIENTS WITH HEART FAILURE AND PRESERVED SYSTOLIC FUNCTION: IS THERE A PLACE FOR AN INFORMED CHOICE?
by: I. V. Zhirov, et al.
Published: (2013-12-01)

Comparison of platelet hemostasis effects for angiotensin receptor blockers in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2007-08-01)

The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
by: Mingfei Li, et al.
Published: (2021-01-01)

Place of imidazoline receptor agonists in the treatment of arterial hypertension
by: D. V. Nebieridze, et al.
Published: (2023-12-01)

Clinical pharmacogenetics of angiotensin II receptor blockers: new perspectives of pharmacotherapy individualization
by: D. A. Sychev, et al.
Published: (2006-04-01)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
by: Hye-Ran Jun, et al.
Published: (2021-01-01)

Effectiveness of an angiotensin II receptor blocker losartan as monoand combined therapy in hypertensive patients with various levels of renin-angiotensin-aldosterone system activity
by: Sh. V. Akhadov, et al.
Published: (2011-02-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01)

INHIBITION OF KIDNEY DISORDERS IN CARDIOVASCULAR DISEASES: THE ROLE OF ANGIOTENSIN II RECEPTOR BLOCKERS
by: V. V. Fomin
Published: (2016-01-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Place of imidazoline receptor agonists in the treatment of hypertension
by: D. V. Nebieridze, et al.
Published: (2022-01-01)

Effect of insertion/deletion polymorphism of angiotensin-converting enzyme gene on efficacy of antihypertensive therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-01-01)

COMBINATION OF DIRECT RENNIN INHIBITOR - ALISKIREN, ANGIOTENSIN II RECEPTOR BLOCKER - VALSARTAN, AND CALCIUM CHANNEL BLOCKER - AMLODIPINE, IN THERAPY OF HYPERTENSIVE PATIENT WITH GOUT (CASE REPORT)
by: O. V. Dralova, et al.
Published: (2016-01-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2012-09-01)

Efficacy of angiotensin receptor blockers for erectile dysfunction in hypertensive men: A systematic review
by: Swati Sucharita Dash, et al.
Published: (2024-01-01)

Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus
by: Ivona Yanovna Yarek-Martynova, et al.
Published: (2010-06-01)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
by: Kenichiro Kinouchi, et al.
Published: (2011-01-01)

Reducing the Risk of Developing Diabetes: The Role of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors in Patients With Hypertension Combined Prediabetes
by: Chenyu Yang, et al.
Published: (2025-05-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Angiotensin receptor blockers: rational prescription tailored to the cardiovascular risk and comorbidities
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

Labial adhesions due to vulvovaginal lichen planus suspected to be caused by angiotensin II receptor blocker
by: Yugo Sawada, et al.
Published: (2025-03-01)

Effect of angiotensin II receptor blocker therapy on markers of fibrosis and immune inflammation in hypertensive patients with chronic kidney disease after ischemic stroke
by: O. A. Osipova, et al.
Published: (2021-11-01)

Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis
by: Haotian Ma, et al.
Published: (2021-01-01)

Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients
by: Ali Kaan Güren, et al.
Published: (2025-04-01)

Isolated systolic arterial hypertension
by: L. G. Ratova, et al.
Published: (2007-04-01)

Comparative efficacy and predictive value of fixed combination of amlodipine and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in patients with coronary heart disease, post-infarction cardiosclerosis and hypertension
by: M. M. Dolzhenko, et al.
Published: (2021-11-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Smoking and Angiotensin-converting Enzyme Inhibitor/Angiotensin Receptor Blocker Cessation to Limit Coronavirus Disease 2019
by: Marco Rossato, et al.
Published: (2020-07-01)

Inhibition of angiotensin Ⅱ type 1 receptor on Renal Fibrosis and Podocyte Damage in Angiotensin Ⅱ-induced Hypertensive Nephropathy
by: Zhang He-ping, et al.
Published: (2022-04-01)

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors
by: R. D. Smith, et al.
Published: (2010-12-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Angiotensin II type 1 receptor antagonists and their combinations in the treatment of hypertension
by: J.A. Ker
Published: (2012-06-01)

A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?
by: M. Greathouse
Published: (2011-10-01)